Market closed

Lucid Diagnostics/LUCD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Lucid Diagnostics

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Ticker

LUCD
Trading on

Industry

Health Care Equipment & Supplies

Employees

70

LUCD Metrics

BasicAdvanced
$44M
Market cap
-
P/E ratio
-$1.22
EPS
1.45
Beta
-
Dividend rate
$44M
1.45
$1.58
$0.63
173K
1.749
1.654
13.48
89.104
-251.78%
-72.72%
-300.52%
9.457
-1.08
-1.05
-0.834
379.19%
-16.01%
5.75%

What the Analysts think about LUCD

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Lucid Diagnostics stock.

LUCD Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

LUCD Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy LUCD

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Lucid Diagnostics stock?

Lucid Diagnostics (LUCD) has a market cap of $44M as of October 06, 2024.

What is the P/E ratio for Lucid Diagnostics stock?

The price to earnings (P/E) ratio for Lucid Diagnostics (LUCD) stock is 0 as of October 06, 2024.

Does Lucid Diagnostics stock pay dividends?

No, Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders as of October 06, 2024.

When is the next Lucid Diagnostics dividend payment date?

Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders.

What is the beta indicator for Lucid Diagnostics?

Lucid Diagnostics (LUCD) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.